NEW YORK (GenomeWeb News) – Rosetta Genomics today said it has received full payment from Sanra Laboratories to settle a dispute over Sanra's purchase of Parkway Clinical Laboratories from Rosetta in 2009.

Sanra paid Rosetta $625,000 as part of the settlement announced last month between the firms. Under the terms of the agreement, Sanra agreed to pay Rosetta $625,000 on top of all other payments it has paid Rosetta "for total consideration of all their obligations." Sanra previously paid Rosetta $10,000 up front.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.